The DOI matches its Crossref record, with a small difference in title or year.
Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): Results From the Recruitment Phase of the PRELAPSE Trial
Abstract
OBJECTIVE To document the acceptability of treatment with long-acting injectable (LAI) antipsychotic medication to early-phase schizophrenia patients as demonstrated by enrollment in a cluster-randomized LAI clinical trial. METHODS Eligible patients aged 18-35 years with a DSM-5 diagnosis of schizophrenia and less than 5 years of lifetime antipsychotic use were recruited between December 2014 and December 2016. Training for LAI antipsychotic site staff included education regarding the role of nonadherence in relapse/hospitalization and the rationale for LAI antipsychotic use with early-psychosis patients, training in shared decision-making and communication strategies, review of frequently asked questions about LAI antipsychotics, and role-playing to develop skills and solutions to overcoming LAI antipsychotic logistical barriers. Study prescribers also received training on prescribing guidelines. RESULTS At the 19 US outpatient clinics randomized to provide LAI antipsychotic treatment, 576 potential participants were identified who met inclusion criteria based on a screening interview. Of these, 83 (14.4%) declined participation because they would not consider LAI antipsychotic treatment and 165 (28.6%) declined for other reasons, resulting in 328 providing written study consent. The first post-consent visit included detailed evaluations to confirm inclusion/exclusion criteria. Thirty-nine participants who consented did not complete this evaluation and 55 were found to not m…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Still being checked.
Cited by
Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2020.2076 · Cited by 208
Self-citationFiorillo, A., Barlati, S., Bellomo, A., Corrivetti, G., Nicolò, G., Sampogna, G., Stanga, V., Veltro, F., Maina, G., & Vita, A. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00293-4 · Cited by 110
“The SDM seems to be particularly effective in the case of LAIs prescription, since patient have prejudices and fears related to the formulation, which the doctor must contrast [35].”
BackgroundMethodInfluentialKane, J. M., McEvoy, J. P., Correll, C. U., & Llorca, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00861-6 · Cited by 93
Self-citationLong-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
Haddad, P. M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181073 · Cited by 63
Self-citationAdvances in Long-Acting Agents for the Treatment of HIV Infection
Rana, A., Castillo‐Mancilla, J., Tashima, K. T., & Landovitz, R. J. (2020) · Drugs · doi:10.1007/s40265-020-01284-1 · Cited by 52
Chmielowska, M., Zisman‐Ilani, Y., Saunders, R., & Pilling, S. (2023) · International Journal of Social Psychiatry · doi:10.1177/00207640221140291 · Cited by 57
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patel, M. X., Bent‐Ennakhil, N., Sapin, C., di Nicola, S., Loze, J.-Y., Nylander, A.-G., & Heres, S. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02530-2 · Cited by 44
Simoni, J. M., Beima‐Sofie, K., Wanje, G., Mohamed, Z. H., Tapia, K. A., McClelland, R. S., Ho, R. J. Y., Collier, A. C., & Graham, S. M. (2021) · Journal of the International Association of Providers of AIDS Care (JIAPAC) · doi:10.1177/23259582211000517 · Cited by 38
Current and emerging long-acting antipsychotics for the treatment of schizophrenia
de Filippis, R., Fazio, P. D., Gaetano, R., Steardo, L., Cedro, C., Bruno, A., Zoccali, R. A., & Muscatello, M. R. A. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1910674 · Cited by 47
Højlund, M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2228686 · Cited by 40
Self-citationTransdermal Delivery of Antipsychotics: Rationale and Current Status
Abruzzo, A., Cerchiara, T., Luppi, B., & Bigucci, F. (2019) · CNS Drugs · doi:10.1007/s40263-019-00659-7 · Cited by 32
Management of schizophrenia and comorbid substance use disorders: expert review and guidance
Neyra, A., Parro-Torres, C., Ros‐Cucurull, E., Machado, I. C., Echarri, E., & Torrens, M. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00529-7 · Cited by 38
Arango, C., Fagiolini, A. M., Gorwood, P. A. P. M., Kane, J. M., Diaz-Mendoza, S., Sahota, N., & Correll, C. U. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04928-0 · Cited by 27
Self-citationFu, A. Z., Pesa, J. A., Lakey, S. L., & Benson, C. J. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03895-2 · Cited by 30
Peters, L., Krogmann, A., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1114-0 · Cited by 27
Self-citationReymann, S., Schoretsanitis, G., Egger, S., Mohonko, A., Kirschner, M., Vetter, S., Homan, P., Seifritz, E., & Burrer, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030441 · Cited by 22
Robinson, D. G., Suett, M., Wilhelm, A., Chaijale, N., Franzenburg, K. R., Gandhi, S. K., Cloud, B., & Mychaskiw, M. A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02455-8 · Cited by 25
Self-citationKane, J. M., Chen, A., Lim, S., Mychaskiw, M. A., Tian, M., Wang, Y., Suett, M., & Rubio, J. M. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000452 · Cited by 24
Self-citationPérez‐Revuelta, J. I., González‐Sáiz, F., Paño, J. M. P., Mongil-Sanjuan, J. M., Rodríguez‐Gómez, C., Muñoz-Manchado, L. I., Mestre-Morales, J., Berrocoso, E., & Moreno, J. M. V. (2023) · Patient Education and Counseling · doi:10.1016/j.pec.2023.107656 · Cited by 21
Fitzgerald, H. M., Shepherd, J., Bailey, H. M. L., Berry, M., Wright, J., & Chen, M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s330936 · Cited by 19
Agid, O., Remington, G. J., Fung, C., Nightingale, N., Duclos, M., & Anger, G. J. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/07067437211055413 · Cited by 17
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis
Qubad, M., Dupont, G., Hahn, M., Martin, S. S., Püntmann, V. O., Nagel, E. C., Reif, A., & Bittner, R. A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01100-4 · Cited by 20
The pharmacological treatment of schizophrenia: how far have we come?
Rubio, J. M., & Kane, J. M. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.13 · Cited by 13
“71 The main intervention of this cluster ‐ randomized trial was training clinicians on how to talk to patients about LAIs in the experimental clinics as compared to those in the clinics delivering usual care.”
BackgroundResultSelf-citationChen, W. J., Liu, C., Liu, C.-C., Kuo, P., Chan, H., Lin, Y., Chung, Y.-C. E., & Chen, W. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.17006 · Cited by 15
Kane, J. M., Agid, O., Castle, D. J., Citrome, L., Fagiolini, A. M., Kishimoto, T., Larrauri, C. A., Leucht, S., Rubio, J. M., Sajatovic, M., et al. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00838-3 · Cited by 20
Self-citationCai, C., Kozma, C. M., Patel, C. A., Benson, C. J., Yunusa, I. U., Zhao, P., Reeder, G., Narasimhan, M., & Bank, R. L. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.6.549 · Cited by 20
The place of long-acting injectable antipsychotics in the treatment of schizophrenia
Kane, J. M., & Rubio, J. M. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231157219 · Cited by 14
Self-citationCorrell, C. U. (2025) · CNS Spectrums · doi:10.1017/s1092852925100503 · Cited by 12
Self-citationSun, Y., Tong, J., Feng, Y., Fang, H., Jiang, T., Zhao, L., Wang, Q., & Yang, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.951544 · Cited by 10
Preventing disease progression in schizophrenia: What are we waiting for
Lieberman, J. A., Mendelsohn, A. I., Goldberg, T. E., & Emsley, R. A. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.12.042 · Cited by 11
Baune, B. T. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2287612 · Cited by 10
Carroll, A. J., Robinson, D. G., Kane, J. M., Kordon, A., Bannon, J. E., Walunas, T. L., & Brown, C. H. (2024) · Frontiers in Health Services · doi:10.3389/frhs.2024.1385398 · Cited by 8
Self-citationCorrell, C. U., Rubio, J. M., Citrome, L., Mychaskiw, M. A., Thompson, S., Franzenburg, K. R., Suett, M., Kotak, S. V., & Kane, J. M. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s477674 · Cited by 8
Self-citationFang, C. Z., Chan, J. K. N., Solmi, M., Wong, C. S. M., Lui, S. S. Y., Correll, C. U., & Chang, W. C. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.05.003 · Cited by 9
Self-citationSchizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia
Schoretsanitis, G., & Correll, C. U. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2474126 · Cited by 7
Self-citationRating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
Ifteni, P. I., Petric, P. S., & Teodorescu, A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.767756 · Cited by 10
Hassib, L., Kanashiro, A., Pedrazzi, J. F. C., Vercesi, B. F., Higa, S., Arruda, Í., Soares, Y., de Souza, A. P., Jordão, A. A., Guimarães, F. S., et al. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100923 · Cited by 9
Stip, É., Grignon, S., Roy, M., Bloom, D., Osman, O. T., Amiri, L., Aziz, K. A., Javaid, S. F., & Arnone, D. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1826930 · Cited by 5
Franzenburg, K. R., Hansen, R., Suett, M., Yaari, A., Levin, A. P., Sergerie, M., Kaplan, S., Sedigh, K., Heres, S., & Sajatovic, M. (2025) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaf032 · Cited by 4
Jin, L., Chen, Y., Zhu, J., Huang, Q., Li, B., Xu, Y., Xi, R., & Lu, W. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.779563 · Cited by 4
Michaels, T. I., Simon-Pearson, L., Kane, J. M., & Cornblatt, B. A. (2024) · Psychiatric Services · doi:10.1176/appi.ps.20230120 · Cited by 4
Self-citationThe Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia
Harrison, S. J., Antunes, J., Knight, K., Johnston, K., Mehawej, J., Sanchez, P., & Correll, C. U. (2026) · CNS Drugs · doi:10.1007/s40263-026-01294-9 · Cited by 3
Self-citationThroneberry, A. R., Burk, B. G., & Pruett, B. S. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1659290 · Cited by 5
When I use a word . . . The languages of medicines—trade names, proprietary names, or brand-names
Aronson, J. K. (2024) · BMJ · doi:10.1136/bmj.q1206 · Cited by 3
Long-Acting Injectable Antipsychotics
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_18 · Cited by 4
Schöttle, D., Janetzky, W., Therrien, F., & Wiedemann, K. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04651-w · Cited by 2
Janzen, D., Bolton, J. M., Leong, C., Kuo, I. F., & Alessi‐Severini, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879224 · Cited by 4
Citrome, L., & Matthews, D. (2025) · CNS Spectrums · doi:10.1017/s1092852925100680 · Cited by 2
First-Episode & Early Psychosis in Transition-Age Youth
Faraji, P., Camp, C., Elberg, Z., & Usher, C. T. (2021) · Springer eBooks · doi:10.1007/978-3-030-62113-1_14
Tracking Oral Antipsychotic Adherence
Meyer, J. M., & Stahl, S. M. (2021) · Cambridge University Press eBooks · doi:10.1017/9781009002103.007
Kuru, E., & Özdemir, İ. (2023) · doi:10.22541/au.168184085.58902721/v1
Arifin, S., & Zaini, M. (2023) · Health & Medical Sciences · doi:10.47134/phms.v1i4.55 · Cited by 1
Sanzone, E. M., Kam, O., Sanzone, K., Bai, M. Y., Rodecker, N., Shad, M. U., Varghese, S. P., Barlati, S., Kirschner, M., Kooner, P., et al. (2024) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000807
Correll, C. U., Yildirim, M., Zhang, Z., Palma, A. M., Pham, T., & Pflug, B. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117091
Self-citationEffects of a pharmacist-led GAIN approach on long-acting injectables in schizophrenia
Karashima, M., Hiraide, M., Onuma, K., Kamasako, M., Fukasawa, A., Sugi, T., Ishii‐Nozawa, R., & Koriki, N. (2026) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2026.103143
Alharbi, M., Alshubaily, B., Fallata, E. O., Althagafi, E., & Almuqahwi, M. S. A. (2026) · Middle East Current Psychiatry · doi:10.1186/s43045-026-00640-3
Franzenburg, K. R., Hansen, R., Suett, M., Yaari, A., Kaplan, S., Sedigh, K., Yu, D., Heres, S., & Sajatovic, M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117452
Metadata
- Authors
- Kane, J. M., Schooler, N. R., Marcy, P., Achtyes, E. D., Correll, C. U., & Robinson, D. G.
- Affiliations
- Feinstein Institute for Medical Research (US)
- SUNY Downstate Health Sciences University (US)
- Vanguard (United States) (US)
- Grand Rapids Public Library (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2019-04-23
- Volume
- 80
- Issue
- 3
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W2940449852
- Semantic Scholar
- 586937481f09b596a545c8e029280b0933d876c8
- Cited by
- 58
- References
- 0
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 11 · 2023: 12 · 2022: 5 · 2021: 10 · 2020: 5 · 2019: 3
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Social Sciences › Psychology › Clinical Psychology › Healthcare Decision-Making and Restraints
- Keywords
- long-acting injectable antipsychotics, early-phase schizophrenia, treatment acceptability, treatment refusal, clinical trial recruitment, employee training, shared decision-making, outpatient clinics, young adults
- MeSH terms
- Aripiprazole, Decision Making, Shared, Adolescent, Adult, Delayed-Action Preparations, Female, Humans, Injections, Male, Patient Acceptance of Health Care, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, United States, Cohort Studies, Secondary Prevention, Young Adult, Early Medical Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.